Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
Amgen gets a full approval for Imdelltra
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
